Table 2.
Sequences and binding affinities of PBF‐derived peptides with HLA‐A*2402 binding motif
| Peptide | Position | Sequence | Binding score† | HLA‐peptide binding affinity‡ (% MFI increase ± SD) |
|---|---|---|---|---|
| A24.1 | 84–93 | WYGGQECTGL | 200 | –3.0 ± 3.2 |
| A24.2 | 145–153 | AYRPVSRNI | 84 | 119.2 ± 7.3 |
| A24.3 | 409–418 | AYQALPSFQI | 75 | 25.3 ± 6.0 |
| A24.4 | 254–263 | GFETDPDPFL | 30 | 2.6 ± 10.3 |
| A24.5 | 320–328 | DFYYTEVQL | 20 | 2.3 ± 9.6 |
| A24.6 | 118–127 | RVEEVWLAEL | 15.8 | 22.5 ± 9.6 |
| A24.7 | 254–262 | GFETDPDPF | 15 | –1.2 ± 5.9 |
| A24.8 | 12–20 | RSLLGARVL | 12 | 14.2 ± 5.8 |
| A24.9 | 415–424 | SFQIPVSPHI | 10.5 | 11.7 ± 7.9 |
| A24.10 | 104–113 | VTVWlLEQKL | 9.5 | 7.1 ± 1.2 |
| HIV | RYLRDQQLLGI | 41.2 ± 9.3 |
†
Binding score was determined by BIMAS HLA Peptide Binding Predictions.
‡
‡The affinity of each peptide was evaluated by a HLA class I stabilization assay. BIMAS, bioinformatics and molecular analysis section; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; PBF, papillomavirus binding factor; SD, standard deviation.